A detailed history of Letko, Brosseau & Associates Inc transactions in Biogen Inc. stock. As of the latest transaction made, Letko, Brosseau & Associates Inc holds 132,912 shares of BIIB stock, worth $19.8 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
132,912
Previous 112,672 17.96%
Holding current value
$19.8 Million
Previous $26.1 Million 1.36%
% of portfolio
0.48%
Previous 0.51%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$189.07 - $236.8 $3.83 Million - $4.79 Million
20,240 Added 17.96%
132,912 $25.8 Million
Q2 2024

Aug 06, 2024

BUY
$190.52 - $236.72 $1.4 Million - $1.74 Million
7,365 Added 6.99%
112,672 $26.1 Million
Q1 2024

May 08, 2024

BUY
$212.02 - $267.71 $189,333 - $239,065
893 Added 0.86%
105,307 $22.7 Million
Q4 2023

Feb 12, 2024

SELL
$222.59 - $267.94 $846,954 - $1.02 Million
-3,805 Reduced 3.52%
104,414 $27 Million
Q3 2023

Nov 09, 2023

SELL
$253.3 - $285.89 $244,687 - $276,169
-966 Reduced 0.88%
108,219 $27.8 Million
Q2 2023

Aug 10, 2023

SELL
$275.25 - $318.06 $1.8 Million - $2.08 Million
-6,540 Reduced 5.65%
109,185 $31.1 Million
Q1 2023

May 11, 2023

SELL
$256.56 - $292.34 $85,434 - $97,349
-333 Reduced 0.29%
115,725 $32.2 Million
Q4 2022

Feb 10, 2023

SELL
$252.44 - $306.72 $825,478 - $1 Million
-3,270 Reduced 2.74%
116,058 $32.1 Million
Q3 2022

Nov 10, 2022

SELL
$194.69 - $268.46 $573,362 - $790,614
-2,945 Reduced 2.41%
119,328 $31.9 Million
Q2 2022

Aug 09, 2022

BUY
$187.54 - $223.02 $29,068 - $34,568
155 Added 0.13%
122,273 $24.9 Million
Q1 2022

May 11, 2022

SELL
$193.77 - $244.14 $242,793 - $305,907
-1,253 Reduced 1.02%
122,118 $25.7 Million
Q4 2021

Feb 09, 2022

BUY
$223.92 - $287.77 $755,730 - $971,223
3,375 Added 2.81%
123,371 $29.6 Million
Q3 2021

Nov 03, 2021

SELL
$282.99 - $369.05 $1.31 Million - $1.71 Million
-4,640 Reduced 3.72%
119,996 $34 Million
Q2 2021

Jul 29, 2021

SELL
$259.0 - $414.71 $500,388 - $801,219
-1,932 Reduced 1.53%
124,636 $43.2 Million
Q1 2021

May 11, 2021

SELL
$242.95 - $284.63 $1.05 Million - $1.23 Million
-4,320 Reduced 3.3%
126,568 $35.4 Million
Q4 2020

Feb 05, 2021

SELL
$236.26 - $355.63 $2.53 Million - $3.81 Million
-10,715 Reduced 7.57%
130,888 $32 Million
Q3 2020

Nov 09, 2020

SELL
$264.77 - $305.71 $3.97 Million - $4.58 Million
-14,995 Reduced 9.58%
141,603 $40.2 Million
Q2 2020

Aug 07, 2020

SELL
$258.66 - $342.55 $1.93 Million - $2.55 Million
-7,448 Reduced 4.54%
156,598 $41.9 Million
Q1 2020

May 14, 2020

BUY
$268.85 - $341.04 $613,784 - $778,594
2,283 Added 1.41%
164,046 $51.9 Million
Q4 2019

Feb 07, 2020

SELL
$220.06 - $304.07 $1.51 Million - $2.09 Million
-6,870 Reduced 4.07%
161,763 $48 Million
Q3 2019

Nov 05, 2019

SELL
$217.44 - $243.88 $2.29 Million - $2.56 Million
-10,515 Reduced 5.87%
168,633 $39.3 Million
Q2 2019

Aug 01, 2019

SELL
$219.29 - $241.72 $1.49 Million - $1.64 Million
-6,795 Reduced 3.65%
179,148 $41.9 Million
Q1 2019

May 10, 2019

SELL
$216.71 - $338.96 $1.16 Million - $1.81 Million
-5,345 Reduced 2.79%
185,943 $44 Million
Q4 2018

Feb 08, 2019

SELL
$278.5 - $352.75 $2.92 Million - $3.69 Million
-10,473 Reduced 5.19%
191,288 $57.6 Million
Q3 2018

Nov 08, 2018

SELL
$293.51 - $383.83 $1.79 Million - $2.34 Million
-6,087 Reduced 2.93%
201,761 $71.3 Million
Q2 2018

Aug 07, 2018

SELL
$257.52 - $306.91 $74,680 - $89,003
-290 Reduced 0.14%
207,848 $60.3 Million
Q1 2018

May 08, 2018

SELL
$260.13 - $367.91 $1.4 Million - $1.98 Million
-5,375 Reduced 2.52%
208,138 $57 Million
Q4 2017

Feb 20, 2018

SELL
$307.64 - $344.58 $1.32 Million - $1.48 Million
-4,290 Reduced 1.97%
213,513 $68 Million
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $61.2 Million - $71.8 Million
217,803
217,803 $68.2 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Letko, Brosseau & Associates Inc Portfolio

Follow Letko, Brosseau & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Letko, Brosseau & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Letko, Brosseau & Associates Inc with notifications on news.